| Metric | Value | Detail |
|---|---|---|
| Revenue | $29.4B | +2.4% YoY |
| Net income | $8.5B | 28.9% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | 34.0% | Operating income / revenue |
| Return on equity | 38% | Net income / equity |
| Return on assets | 14% | Net income / assets |
| Revenue growth (YoY) | +2.4% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +2.6% | Compound annual |
| Diluted EPS | $6.84 | FY2025 |
| Debt-to-equity | 1.10 | Long-term debt / equity |
| Current ratio | 1.55 | Current assets / liabilities |
| Cash & equivalents | $7.6B | Balance sheet |
| Total assets | $59.0B | FY2025 year-end |
| Shareholders’ equity | $22.6B | FY2025 year-end |
| Share price | $129.83 | Delayed · 2026-07-10 |
| Market cap | $161.2B | Price × shares outstanding |
| P/E ratio | 18.9 | Market cap / net income |
| P/S ratio | 5.5 | Market cap / revenue |
| Dividend yield | 2.43% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
GILEAD SCIENCES, INC. (GILD) stock fundamentals
GILEAD SCIENCES, INC. (GILD) reported $29.4B in revenue and $8.5B in net income in fiscal 2025, a 28.9% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $161.2B at a delayed share price. It scores 65/100 on WealthyBud's Investor Score, ranking #15 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$29.4B
▲ +2.4% YoY
Net income
$8.5B
28.9% net margin
Market cap
$161.2B
Price $129.83 · delayed
P/E ratio
18.9
Price / earnings
Return on equity
38%
Net income / equity
Investor Score
65/100
#15 of 100 covered
GILEAD SCIENCES, INC. fundamentals at a glance
The table summarizes GILEAD SCIENCES, INC.'s key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is GILEAD SCIENCES, INC.?
GILEAD SCIENCES, INC. runs a 28.9% net margin and n/a gross margin in fiscal 2025, turning $29.4B of revenue into $8.5B of profit. Return on equity is 38% and return on assets 14%.
Is GILEAD SCIENCES, INC. growing?
GILEAD SCIENCES, INC.'s revenue changed +2.4% in fiscal 2025 and compounded at +2.6% a year over three years, reaching $29.4B. Diluted earnings per share were $6.84 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $27.3B | n/a |
| 2022 | $27.3B | -0.1% |
| 2023 | $27.1B | -0.6% |
| 2024 | $28.8B | +6.0% |
| 2025 | $29.4B | +2.4% |
How is GILEAD SCIENCES, INC. valued?
GILEAD SCIENCES, INC. carries a market capitalization of $161.2B at a delayed share price of $129.83, trading at a 18.9 price-to-earnings ratio and 5.5 price-to-sales with a 2.43% dividend yield. Its Value subscore is 59/100 across the covered universe.
How financially healthy is GILEAD SCIENCES, INC.?
GILEAD SCIENCES, INC. ended fiscal 2025 with $7.6B in cash, a debt-to-equity ratio of 1.10 and a current ratio of 1.55. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is GILEAD SCIENCES, INC.'s Investor Score?
GILEAD SCIENCES, INC. scores 65/100 on WealthyBud's Investor Score, #15 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
65/100
#15 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
GILEAD SCIENCES, INC. (GILD) stock FAQ
How much revenue does GILEAD SCIENCES, INC. make?
GILEAD SCIENCES, INC. (GILD) reported $29.4B in revenue in fiscal 2025, +2.4% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +2.6% a year.
Is GILEAD SCIENCES, INC. profitable?
Yes. GILEAD SCIENCES, INC. earned $8.5B in net income in fiscal 2025, a 28.9% net margin. Its return on equity was 38% and return on assets 14%, based on figures from its latest 10-K.
How fast is GILEAD SCIENCES, INC. growing?
GILEAD SCIENCES, INC.'s revenue changed +2.4% year over year in fiscal 2025 and compounded at +2.6% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 52/100 versus the covered universe.
What is GILEAD SCIENCES, INC.'s market cap and P/E ratio?
GILEAD SCIENCES, INC. has a market capitalization of $161.2B at a delayed share price of $129.83, trading at a price-to-earnings ratio of 18.9 and price-to-sales of 5.5. Its dividend yield is 2.43%. Prices are delayed and illustrative.
What is GILEAD SCIENCES, INC.'s WealthyBud Investor Score?
GILEAD SCIENCES, INC. scores 65/100, ranking #15 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (52), profitability (80), returns on capital (78), balance-sheet strength (50) and value (59). It is a research opinion, not investment advice.
Where does this GILEAD SCIENCES, INC. financial data come from?
Fundamentals come from GILEAD SCIENCES, INC.'s annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from GILEAD SCIENCES, INC.’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.